British drug giant GlaxoSmithKline is reportedly set for a new round in its legal tussle with one of its leading rivals – Novartis of Switzerland – over an alleged patent infringement.
The action relates to the production procedure of vaccines against children’s illnesses, including bacterial meningitis. GSK said it first patented the process in 1981. Novartis then had its own patent accepted early this decade. GSK began a lawsuit last year, labelling Novartis’ patent as “weak” and claiming “it should never have been granted”. A hearing…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
